1. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation
- Author
-
Gao, XN, Yan, F, Lin, J, Gao, L, Lu, XL, Wei, SC, Shen, N, Pang, JX, Ning, QY, Komeno, Y, Deng, AL, Xu, YH, Shi, JL, Li, YH, Zhang, DE, Nervi, C, Liu, SJ, and Yu, L
- Subjects
Rare Diseases ,Pediatric Cancer ,Childhood Leukemia ,Cancer ,Pediatric Research Initiative ,Genetics ,Hematology ,Pediatric ,Orphan Drug ,2.1 Biological and endogenous factors ,Aetiology ,Animals ,Apoptosis ,Blotting ,Western ,Cell Proliferation ,Cell Transformation ,Neoplastic ,Chromatin Immunoprecipitation ,Core Binding Factor Alpha 2 Subunit ,DNA (Cytosine-5-)-Methyltransferases ,DNA Methylation ,DNA Methyltransferase 3A ,Flow Cytometry ,Humans ,Hypoxia-Inducible Factor 1 ,alpha Subunit ,Immunoenzyme Techniques ,Leukemia ,Myeloid ,Acute ,Mice ,Oncogene Proteins ,Fusion ,Promoter Regions ,Genetic ,RNA ,Messenger ,RUNX1 Translocation Partner 1 Protein ,Real-Time Polymerase Chain Reaction ,Reverse Transcriptase Polymerase Chain Reaction ,Transcriptional Activation ,Tumor Cells ,Cultured ,Xenograft Model Antitumor Assays ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology - Abstract
The mechanisms by which AML1/ETO (A/E) fusion protein induces leukemogenesis in acute myeloid leukemia (AML) without mutagenic events remain elusive. Here we show that interactions between A/E and hypoxia-inducible factor 1α (HIF1α) are sufficient to prime leukemia cells for subsequent aggressive growth. In agreement with this, HIF1α is highly expressed in A/E-positive AML patients and strongly predicts inferior outcomes, regardless of gene mutations. Co-expression of A/E and HIF1α in leukemia cells causes a higher cell proliferation rate in vitro and more serious leukemic status in mice. Mechanistically, A/E and HIF1α form a positive regulatory circuit and cooperate to transactivate DNMT3a gene leading to DNA hypermethylation. Pharmacological or genetic interventions in the A/E-HIF1α loop results in DNA hypomethylation, a re-expression of hypermethylated tumor-suppressor p15(INK4b) and the blockage of leukemia growth. Thus high HIF1α expression serves as a reliable marker, which identifies patients with a poor prognosis in an otherwise prognostically favorable AML group and represents an innovative therapeutic target in high-risk A/E-driven leukemia.
- Published
- 2015